The design and evaluation of a novel targeted drug delivery system using cationic emulsion-antibody conjugates

被引:24
作者
Goldstein, D
Nassar, T
Lambert, G
Kadouche, J
Benita, S [1 ]
机构
[1] Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, IL-91905 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel
[3] Novagali Pharma, F-91000 Evry, France
[4] MAT, F-91000 Evry, France
基金
以色列科学基金会;
关键词
emulsion; antibody; ferritin; cationic; cancer;
D O I
10.1016/j.jconrel.2005.08.021
中图分类号
O6 [化学];
学科分类号
0703 [化学];
摘要
In an attempt to design a targeted drug delivery system to tumors' over-expressing H-ferritin specifically recognized by a monoclonal antibody, AMB8LK, a cationic emulsion-AMB8LK conjugate was prepared. A novel cross-linker molecule bearing maleimide group was synthesized and added to cationic emulsion formulation for AMB8LK Fab' fragment covalent coupling. NMR spectroscopy confirmed the cross-linker synthesis and the preservation of the active maleimide function. SDS gel-electrophoresis results corroborated the formation of the Fab' fragment. Different densities of Fab' fragments (10-200 Fab'/oil droplet) were conjugated to emulsion droplet interface and no changes in the physico-chemical properties were observed (similar to 120 nm size and zeta potential of similar to+ 30 mV). The coupling efficiency ranged from 55% to 70% and was visualized by TEM showing gold particles attached to the droplet interface. Cell culture studies demonstrated specific binding to cells as confirmed by the occurrence of the marked reduction in binding when free AMB8LK Mab was incubated before adding the AMB8LK-emulsion conjugate to the cells. The coupling of AMB8LK Fab' fragment to the cationic emulsion increased the cells uptake by 50% as compared to non-conjugated respective cationic emulsion. Appropriate conditions were, thus, identified for coupling AMB8LK Fab' fragment to cationic emulsion without altering the specificity and affinity of the Mab fragment to the tumor antigen. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:418 / 432
页数:15
相关论文
共 53 条
[1]
Ligand-targeted therapeutics in anticancer therapy [J].
Allen, TM .
NATURE REVIEWS CANCER, 2002, 2 (10) :750-763
[2]
Immunoliposomes - A promising approach to targeting cancer therapy [J].
Bendas, G .
BIODRUGS, 2001, 15 (04) :215-224
[3]
Improving the efficacy of antibody-based cancer therapies [J].
Carter, P .
NATURE REVIEWS CANCER, 2001, 1 (02) :118-129
[4]
COHEN C, 1984, CANCER, V54, P2190, DOI 10.1002/1097-0142(19841115)54:10<2190::AID-CNCR2820541020>3.0.CO
[5]
2-2
[6]
CRAGG SJ, 1984, BRIT J HAEMATOL, V57, P679, DOI 10.1111/j.1365-2141.1984.tb08557.x
[7]
The radiation biology of radioimmunotherapy [J].
Dixon, KL .
NUCLEAR MEDICINE COMMUNICATIONS, 2003, 24 (09) :951-957
[8]
DRYSDALE JW, 1977, SEMIN HEMATOL, V14, P71
[9]
Preparation and characterization of doxorubicin-loaded sterically stabilized immunoliposomes [J].
Emanuel, N ;
Kedar, E ;
Bolotin, EM ;
Smorodinsky, NI ;
Barenholz, Y .
PHARMACEUTICAL RESEARCH, 1996, 13 (03) :352-359
[10]
The development of monoclonal antibodies for the therapy of cancer [J].
Farah, RA ;
Clinchy, B ;
Herrera, L ;
Vitetta, ES .
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 1998, 8 (3-4) :321-356